product summary
Loading...
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
antibody
product name :
Mouse anti Respiratory Syncytial Virus Fusion Protein
catalog :
MCA490
quantity :
1 mg
price :
680 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
RSV3216 (B016)
application :
western blot, ELISA, immunocytochemistry, immunoprecipitation, flow cytometry
more info or order :
citations: 9
Reference
Persson B, Jaffe A, Fearns R, Danahay H. Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS ONE. 2014;9:e102368 pubmed publisher
Hägglund S, Hu K, Blodörn K, Makabi Panzu B, Gaillard A, Ellencrona K, et al. Characterization of an experimental vaccine for bovine respiratory syncytial virus. Clin Vaccine Immunol. 2014;21:997-1004 pubmed publisher
Bird G, Boyapalle S, Wong T, Opoku Nsiah K, Bedi R, Crannell W, et al. Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection. J Clin Invest. 2014;124:2113-24 pubmed publisher
Wong T, Boyapalle S, Sampayo V, Nguyen H, Bedi R, Kamath S, et al. Respiratory syncytial virus (RSV) infection in elderly mice results in altered antiviral gene expression and enhanced pathology. PLoS ONE. 2014;9:e88764 pubmed publisher
He J, Sun E, Bujny M, Kim D, Davidson M, Zhuang X. Dual function of CD81 in influenza virus uncoating and budding. PLoS Pathog. 2013;9:e1003701 pubmed publisher
Shaw C, Galarneau J, Bowenkamp K, Swanson K, Palmer G, Palladino G, et al. The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease. Vaccine. 2013;31:306-12 pubmed publisher
Adams O, Bonzel L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis. 2010;51:185-8 pubmed publisher
Kolokoltsov A, Deniger D, Fleming E, Roberts N, Karpilow J, Davey R. Small interfering RNA profiling reveals key role of clathrin-mediated endocytosis and early endosome formation for infection by respiratory syncytial virus. J Virol. 2007;81:7786-800 pubmed
Fleming E, Kolokoltsov A, Davey R, Nichols J, Roberts N. Respiratory syncytial virus F envelope protein associates with lipid rafts without a requirement for other virus proteins. J Virol. 2006;80:12160-70 pubmed publisher
product information
Entity Type :
Monoclonal Antibody
Entity Category :
Antibodies
ProductCode :
MCA490
Description :
Mouse anti Respiratory Syncytial Virus Fusion Protein
Specificity :
Respiratory Syncytial Virus Fusion Protein
TargetSpecies :
Viral
Host :
Mouse
Format :
Purified
Isotypes :
IgG2b
Applications :
WB,E,IF,IP,F,EM
ApplicationTypes :
Western Blotting,ELISA,Immunofluorescence,Immunoprecipitation,Flow Cytometry,Immuno-electron Microscopy
Clone :
RSV3216 (B016)
Quantity :
1 mg
Quantity Value :
1
Quantity Type :
mg
Published Synonyms :
RSV
Entity Formats :
Purified
UNSPSC :
41116161
Concentration :
IgG concentration 1.0 mg/ml
Product Form :
Purified IgG - liquid
PriceGBP :
486
PriceEUR :
680
PriceUSD :
680 USD
PriceCHF :
740
PriceSEK :
7752
PriceNOK :
7741
PriceDKK :
5072
NotForSaleInCountries :
AU
more info or order :
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.